QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study

Eur Respir J. 2018 Aug 16;52(2):1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug.

Lorenzo Guglielmetti^{1

2

3}, Simon Tiberi^{4

5}, Matthew Burman⁵, Heinke Kunst⁵, Christian Wejse⁶, Tamar Togonidze⁷, Graham Bothamley⁸, Christoph Lange^{9

10

11}; TBnet; of the TBnet QTc survey

¹ APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
² Sorbonne Université, Université Pierre et Marie Curie 06, Unité 1135, Team E13 (Bactériologie), CR7 INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
³ Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France.
⁴ Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
⁵ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁶ Dept of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
⁷ National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
⁸ Dept of Respiratory Medicine, Homerton University Hospital, London, UK.
⁹ Division of Clinical Infectious Diseases, Medical Clinic Research Center Borstel, German Center for Infection Research (DZIF), Clinical Tuberculosis Center, Borstel, Germany.
¹⁰ International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
¹¹ Dept of Medicine, Karolinska Institute, Stockholm, Sweden.

No abstract available

Publication types